Marcadores ecográficos de cromosomopatías en el I trimestre de la gestación: translucencia nucal
Resumen
La translucencia nucal se comporta como el marcador primario por excelencia en el I trimestre del embarazo, en gestaciones únicas o múltiples, de bajo o alto riesgo genético, no solo para discriminar las cromosomopatías, sino también por su importante asociación en fetos
euploides con mayor probabilidad de padecer malformaciones severas, sobre todo cardíacas. Sin embargo, la valoración óptima del riesgo incluye la consideración de otros factores, entre ellos la edad materna, antecedentes familiares y marcadores bioquímicos.
Palabras clave
Texto completo:
PDFReferencias
Díaz Recaséns J, Plaza Arranz J, Fernández Moya JM. Malformaciones congénitas: clasificación y formas
comunes. En: Cabero Roura L. Tratado de Ginecología, Obstetricia y Medicina de la Reproducción. Madrid:
Editorial Médica Panamericana; 2003.p. 977-94.
Carreras Moratonas E, Higueras Sanz T. Marcadores ecográficos de cromosomopatías En: Cabero Roura L.
Tratado de Ginecología, Obstetricia y Medicina de la Reproducción. Madrid: Editorial Médica Panamericana;
p. 1016-23.
Szabo J, Gellen J. Nuchal fluid accumulation in trisomy-21 detected by vaginosonography in first trimester. Lancet 1990; 336:1133.
Bilardo CM, Müller MA, Pajkrt E. Outcome of fetuses with increased nuchal translucency. Curr Opin Obstet
Gynecol 2001; 13:169-74.
Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K. Fetal nuchal translucency: ultrasound screening for
chromosomal defects in first trimester of pregnancy. BMJ 1992; 304:867-9.
Nicolaides KH, Heath V, Cirero S. Increased fetal nuchal translucency at 11-14 weeks. Prenat Diagn 2002;22:308-15.
Sebire NJ, Snijders JM, Hughes K, Sepulveda W, Nicolaides KH. Screening for trisomy 21 in twin pregnancies by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Br J Obstet Gynecol 1996;103:999-1003.
Salomon LJ, Bernard JP, Taupin P, Benard C, Ville Y. Relationship between nuchal translucency at 11-14
weeks and nuchal fold at 20-24 weeks of gestation. Ultrasound Obstet Gynecol. 2001; 18:636-7.
Zoppi MA, Ibba RM, Floris M, Manca F, Axiana C, Monni G. Changes in nuchal translucency thickness in
normal and abnormal karyotype fetuse. BJOG 2003; 110:584-8.
Wilson RD, Venir N, Farquharson DF. Fetal nuchal fluid – physiological or pathological ? – in pregnancies less than 17 menstrual weeks. Prenat Diagn 1992; 12:755-63.
von Kaisenberg CS, Nicolaides KH, Brand-Saberi B. Lymphatic vessel hypoplasia in fetus with Turner
syndrome. Hum Reprod 1999; 14:823-6.
Hyett JA, Noble PL, Sebire NJ, Snijers RJ, Nicolaides KH. Lethal congenital artrogryposis presents with
increased nuchal translucency at 10 – 14 weeks of gestation. Ultrasound Obstet Gynecol 1997; 9:310-3.
Mol BWJ. Down’s syndrome, cardiac anomalies and nuchal translucency. Fetal heart failure might link nuchal translucency and Down`s syndrome. BMJ 1999; 318:70-1
Daskalakis G, Sebire NJ, Jurkovic D, Snijders RJ, Nicolaides KH. Body stalk anomaly at 10-14 weeks of
gestation. Ultrasound Obstet Gynecol 1997; 10:416-8.
Sebire NJ, Snijders RJ, Davenport M, Greenough A, Nicolaides KH. Fetal nuchal translucency thickness at 10-14 week’s gestation and congenital diaphragmatic hernia. Obstet Gynecol 1997; 90: 943-6.
Lam YH, Tang MH, Lee CP, Tse HY. Nuchal translucency in fetuses affected by homozygous alphathalassemia - 1 at 12 – 13 weeks of gestation. Ultrasound Obstet Gynecol 1999; 13:238-40.
Von Kaisenberg CS, Brand-Saberi B, Christ B, Vallian S, Farzaneh F, Nicolaides KH. Collagen type VI gene expression in the skin of trisomy 21 fetuses. Obstet Gynecol 1998; 91:319-23.
Bohlandt S, von Kaisenberg CS, Wewetzer K, Christ B, Nicolaides KH, Brand-Saberi B. Hyaluronan in the
nuchal skin of chromosomally abnormal fetuses. Hum Reprod 2000; 15:1155-8.
Sebire NJ, Bianco D, Snijders RJ, Zuckerman M, Nicolaides KH. Increased fetal nuchal translucency thickness at 10 – 14 weeks: is screening for maternal – fetal infection necessary?. Br J Obstet Gynecol 1997; 104:212-5.
Pandya P: Nuchal translucency thickness En: Nicolaides KH, Sebire NJ, Snijders RJ editors. The 11 – 14 week scan. The diagnosis of fetal abnormalities. Carnforth, England, Parthenon Publishing Group, 1999.p. 15. (Diploma in fetal medicine series).
Braithwaite JM, Morris RW, Economides DL. Nuchal translucency measurements: frequency distribution and
changes with gestation in a general population. Br J Obstet Gynaecol 1996; 103:1201-4.
Whitlow BJ, Chatzipapas IK, Economides DL. The effect of fetal neck position on nuchal translucency
measurement. Br J Obstet Gyencol 1998;105(8):872-6.
Schaefer M, Laurichesse-Delmas H, Ville Y. The effect of nuchal coord on nuchal translucnecy measurement at 10-14 weeks. Ultrasound Obstet Gynecol 1998; 11:271-3.
Kurjak A, Kupesic S, Ivancic-Kosuta MJ. Three-dimensional transvaginal ultrasound improves measurement of nuchal translucency. J Perinat Med 1999; 27:97–102.
Hull AD, James G, Salerno CC, Nelson T, Pretorius DH. Three-dimensional ultrasonography and assessment of the first-trimester fetus. J Ultrasound Med 2001; 20:287-93.
Clementschitsch G, Hasenöhrl G, Schaffer H, Steiner H. Comparison between two- and three-dimensional ultrasound measurements of nuchal translucency. Ultrasound Obstet Gynecol 2001; 18:475-80.
Eppel W, Worda C, Frigo P, Lee A. Three-versus two-dimensional ultrasound for nuchal translucency
thickness measurements: Comparison of feasibility and levels of agreement. Prenat Diagn 2001;21:596-601.
Worda C, Radner, Lee A, Eppel W. Three-dimensional ultrasound for nuchal translucency thickness measurements: Comparison of transabdominal and transvaginal ultrasound. J Soc Gynecol Investig 2003;10:361-5.
Chitty LS, Pandya PP. Ultrasound screening for fetal abnormalities in the first trimester. Prenatal Diag 1997;17:1269-81.
Pajkrt E, Bilardo CM, Van Lith JM, Mol BW, Bleker OP. Nuchal translucency measurement in normal fetuses.Obstet Gynecol 1995; 86:994-7.
Pandya PP, Snijders RJ, Johsohn SP, Brizot de Lourdes M, Nicolaides KH. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 – 14 weeks of gestation. Br J Obstet Gynecol 1995;102:957-62.
Comas C, Muñoz A, Torrents M, Antolín E, Palacio M, Devesa R, et al. Screening precoz de cromosomopatías mediante ecografía y Doppler. Prog Diagn Prenat 1998; 10:450-63.
Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of
trisomy 21 by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Lancet 1998;351:343-6.
Souter V, Nyberg D. Sonographic screening for fetal aneuploidy: first trimester. J Ultrasound Med 2001,
:775-90.
Bewley S, Roberts LJ, MacKinson AM, Rodeck CH. First trimester fetal nuchal translucency: problems with
screening the general population. Br J Obstet Gynaecol 1995; 102:386-8.
Hafner E, Schuchter K, Philipp K. Screening for chromosomal abnormalities in an unselected population by nuchal translucency. Ultrasound Obstet Gynecol 1995; 6:330-3.
Szabo J, Gellen J, Szemere G. First-trimester ultrasound screening for fetal aneuploidies in women over 35 and under 35 years of age. Ultrasound Obstet Gynecol 1995; 5:161-3.
Zimmermann R, Hucha A, Savoldelli G, Binkert F, Achermann J, Grudzinskas JG. Serum parameters and
nuchal translucency in first trimester screening for fetal chromosomal abnormalities. Br J Obstet Gynaecol 1996;103:1009-14.
Biagiotti R, Periti E, Brizzi L, Vanzi E, Cariati E. Comparison between two methods of standardization for gestational age differences in fetal nuchal translucency measurement in first trimester screening for trisomy 21. Ultrasound Obstet Gynecol 1997; 9:248-52.
Taipale P, Hiilesmaa V, Salonen R, Ylostalo P. Increased nuchal translucency as a marker for fetal
chromosomal defects. N Eng J Med 1997; 337:1654-8.
Thilaganathan B, Slack A, Wathen NC. Effect of firsttrimester nuchal translucency on second-trimester
maternal serum biochemical screening for Down’s syndrome. Ultrasound Obstet Gynecol 1997; 10:26-4.
Economides DL, Whitlow BJ, Kadir R, et al. First trimester sonographic detection of chromosomal
abnormalities in an unselected population. Br J Obstet Gynaecol 1998; 105:58-62.
Haddow JE, Palomaki GE, Knight GJ, Williams J, Miller WA, Johnson A. Screening of maternal serum for fetal Down’s syndrome in the first trimester. N Engl J Med 1998; 338:955-61.
Schwarzler P, Carvalho JS, Senat MV, Masroor T, Campbell S, Ville Y. Screening for fetal aneuploidy and
fetal cardiac abnormalities by nuchal translucency thickness measurement at 10–14 weeks gestation as part of routine antenatal care in an unselected population. Br J Obstet Gynaecol 1999; 106:1029-34.
Zoppi MA, Ibba RM, Putzolu M, Floris M, Monni G. Assessment of risk for chromosomal abnormalities at 10–14 weeks of gestation by nuchal translucency and maternal age in 5,210 fetuses at a single centre. Fetal Diagn Ther 2000; 15:170-3.
Gasiorek-Wiens A, Tercanli S, Kozlowski P, Kossakiewicz A, Minderer S, Meyberg H, et al. Screening for trisomy 21 by fetal nuchal translucency and maternal age: multicenter project in Germany, Austria and Switzerland. Ultrasound Obstet Gynecol 2001; 18:645-8.
Crossleya JA, Aitkena DA, Cameronb AD, McBridea E, Connora JM. Combined ultrasound and biochemical
screening for Down’s Syndrome in the first trimester: a Scottish multicentre study. BJOG 2002; 109:667-76.
Comas C, Torrents M, Muñoz A, Antolín E, Figueras F, Echevarrıía M. Measurement of nuchal translucency as a single strategy in trisomy 21 screening: should we use any other marker?. Obstet Gynecol 2002;100:648-54.
Chasen ST, Sharma G, Kalish B, Chervenak FA. First trimester screening for aneuploidy with fetal nuchal
translucency in a United States population. Ultrasound Obstet Gynecol 2003; 22:149-51.
Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al, for the First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium*. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005;353(19):2001-11.
Hyett JA, Sebire NJ, Snijders RJ, Nicolaides KH.
Intrauterine lethality of trisomy 21 fetuses with increased nuchal thickness. Ultrasound Obstet Gynecol 1996; 7:101-3.
Pandya PP, Altman DG, Brizot ML, Pettersen H, Nicolaides KH. Repeatability of measurement of fetal nuchal translucency tickness. Ultrasound Obstet Gynecol 1995; 5:334-7.
Thilaganathan B, Sairam S, Michailidis G, Wathen NC. First trimester nuchal translucency: effective routine
screening for Down's syndrome. Br J Radiol 1999;72:946-8.
Jackson M, Rose NC. Diagnosis and management of fetal nuchal translucency. Semin Roentgenol 1998;33:333-8.
Bronshtein M, Siegler E, Yoffe N, Zimmer EZ. Prenatal diagnosis of ventricular septal defect and overriding aorta at 14 weeks´ gestation, using transvaginal sonography. Prenatal Diagn 1990; 10:697-702.
Gembruch U, Knopfle G, Chatterjee M, Bald R, Hasmann M. First trimester diagnosis of fetal congenital heart disease by transvaginal two-dimensional and Doppler echocardiography. Obstet Gynecol 1990; 75: 496-8.
Achiron R, Rotstein Z, Lipitz S, Mashiach S, Hegesh J. First trimester diagnosis of fetal congenital Herat
disease by transvaginal ultrasonography. Obstet Gynecol 1994; 84:69-72.
Souka AP, Snijders RJ, Novakov A, Soares W, Nicolaides KH. Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10 – 14 weeks of gestation. Ultrasound Obstet Gynecol 1998; 11:391-400.
Hyett JA, Perdu M, Shaland GK, Snijders RJ, Nicolaides KH. Using fetal nuchal translucency to screen for major congenital cardiac defects at 10 – 14 weeks of gestation: population based cohort study. BMJ 1999;318:81-5.
Galindo A, Comas C, Martínez JM, Gutiérrez-Larraya F, Carrera JM, Puerto B, et al. Cardiac defects in
chromosomally normal fetuses with increased nuchal translucency at 10-14 weeks of gestation. J Matern Fetal Neonatal Med 2003; 13:163-70.
Makrydimas G, Sotiriadis A, Ioannidis JP. Screening performance of first-trimester nuchal translucency for
major cardiac defects: a meta-analysis. Am J Obstet Gynecol 2003; 189:1330-5.
Snijders R, Smith E. The role of fetal nuchal translucency in prenatal screening. Curr Opin Obstet Gynecol 2002; 14:577-85.
Sebire NJ, D`Ercole C, Hughes K, Carvalho M,
Nicolaides KH. Increased fetal nuchal translucency thickness at 10-14 weeks of gestation as a predictor of severe twin-to-twin transfusion syndrome. Ultrasound Obstet Gynecol 1997; 10:86-9.
Enlaces refback
- No hay ningún enlace refback.
Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons
---------------------------------------------------------------------------------------------
Mem. Inst. Investig. Cienc. Salud